의약품용 유리 포장 시장 : 시장 예측 - 제품 유형별, 유리 유형별, 포장 형태별, 약제 유형별, 용량별, 최종 사용자별 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Pharmaceutical Glass Packaging Market is accounted for $22.8 billion in 2026 and is expected to reach $37.9 billion by 2034, growing at a CAGR of 6.6% during the forecast period. Pharmaceutical Glass Packaging refers to the comprehensive range of glass containers and packaging solutions designed to protect, preserve, and deliver pharmaceutical products including injectable drugs, vaccines, biologics, and liquid medicines. These solutions encompass vials, ampoules, cartridges, syringes, bottles, and tubular glass containers manufactured from various glass types including Type I borosilicate glass, Type II treated soda-lime glass, Type III soda-lime glass, amber glass, and clear flint glass for primary and secondary packaging applications. This technology helps pharmaceutical companies ensure drug stability, safety, and efficacy while meeting regulatory requirements for container closure systems.

Market Dynamics:

Driver:

Growing demand for biologics and injectable drugs

The increasing demand for biologics, biosimilars, and injectable drugs serves as a primary driver for the Pharmaceutical Glass Packaging market. Biologics and injectable formulations require specialized glass packaging that provides superior chemical durability, thermal stability, and barrier properties to protect sensitive drug products. The rising prevalence of chronic diseases and the growing pipeline of biologic drugs drive demand for high-quality glass packaging. As biologics represent a growing share of pharmaceutical development, the need for reliable glass packaging continues to expand significantly.

Restraint:

High manufacturing costs and supply chain complexities

The significant manufacturing costs and supply chain complexities pose restraints to the Pharmaceutical Glass Packaging market. Producing high-quality pharmaceutical glass requires substantial investment in specialized manufacturing equipment, quality control systems, and regulatory compliance. Supply chain disruptions affecting raw materials including silica sand and energy inputs impact production costs and availability. The complexity of meeting stringent regulatory requirements for container closure systems adds to operational costs. These cost and supply constraints can limit market growth.

Opportunity:

Development of advanced glass coatings and delamination prevention

The development of advanced glass coatings and delamination prevention technologies presents significant opportunities for the Pharmaceutical Glass Packaging market. Innovative coatings improve drug compatibility, reduce protein adsorption, and prevent glass delamination that can compromise drug quality. Surface treatment technologies enhance the chemical durability of glass containers for sensitive biologics. As drug formulations become more complex and sensitive, the demand for advanced glass packaging solutions continues to grow, creating opportunities for manufacturers offering innovative coating technologies.

Threat:

Competition from polymer and plastic packaging alternatives

Competition from polymer and plastic packaging alternatives poses significant threats to the Pharmaceutical Glass Packaging market. Plastic containers offer advantages including reduced breakage, lighter weight, and lower cost for certain applications. Advances in polymer materials have improved compatibility with drug products. The availability of alternatives can pressure glass packaging adoption in applications where chemical compatibility and barrier requirements are less demanding. This competitive dynamic can limit growth in certain segments.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Pharmaceutical Glass Packaging market through increased demand for vaccine packaging and supply chain disruptions. The urgent need for vaccine vials and syringes created unprecedented demand for pharmaceutical glass packaging. Manufacturers expanded production capacity to meet global vaccine packaging requirements. Supply chain challenges including raw material availability and logistics affected production. The pandemic highlighted the critical importance of reliable pharmaceutical packaging supply chains and the essential role of glass packaging in global health.

The vials segment is expected to be the largest during the forecast period

The vials segment is expected to account for the largest market share during the forecast period, driven by the widespread use of glass vials for parenteral drugs, vaccines, and biologics requiring sterile containment. Vials provide superior chemical stability, thermal resistance, and barrier properties essential for sensitive drug products. The growing demand for injectable drugs and vaccines supports continued dominance. As the pharmaceutical industry expands biologic and vaccine development, vials remain the primary packaging choice for parenteral products.

The Type I glass segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Type I glass segment is predicted to witness the highest growth rate, due to the superior chemical durability and thermal stability of borosilicate glass for sensitive biologics and injectable drugs. Type I glass provides excellent resistance to chemical attack and delamination, making it essential for pH-sensitive and high-value drug products. The growing pipeline of biologic drugs and complex formulations drives demand. As pharmaceutical development increasingly focuses on sensitive biologics, Type I glass continues to gain market share.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by substantial investment in pharmaceutical R&D, the presence of major pharmaceutical companies, and strong regulatory requirements for drug packaging. The region's focus on drug safety and quality creates demand for high-quality glass packaging. Significant pharmaceutical spending and the emphasis on biologics development contribute to market leadership. Additionally, robust regulatory frameworks supporting container closure system integrity further fuel adoption in North America.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid growth of the pharmaceutical industry, expanding biologics manufacturing, and increasing healthcare spending across major economies. Countries such as China, India, and South Korea are witnessing significant growth in pharmaceutical production and packaging demand. Government initiatives promoting domestic pharmaceutical manufacturing and the rise of contract development and manufacturing organizations further contribute to regional market expansion.

Key players in the market

Some of the key players in the Pharmaceutical Glass Packaging Market include SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Stevanato Group S.p.A., SGD Pharma, Corning Incorporated, Nipro Corporation, Bormioli Pharma S.p.A., Shandong Pharmaceutical Glass Co. Ltd., Stolzle Glass Group, West Pharmaceutical Services Inc., Ardagh Group S.A., DWK Life Sciences GmbH, Beatson Clark Ltd., Sisecam Group, and Owens-Illinois Inc.

Key Developments:

In June 2026, SCHOTT Pharma announced a major expansion of its pharmaceutical glass packaging production capacity to meet growing demand for vaccine vials and biologics packaging. The expansion includes new glass conversion capabilities and enhanced quality control systems.

In May 2026, Gerresheimer introduced a new line of high-performance glass syringes featuring advanced surface treatment for reduced protein adsorption and improved drug compatibility.

Product Types Covered:

• Vials
• Ampoules
• Cartridges
• Syringes
• Bottles
• Tubular Glass Containers
• Other Glass Containers

Glass Types Covered:

• Type I (Borosilicate Glass)
• Type II (Treated Soda-Lime Glass)
• Type III (Soda-Lime Glass)
• Amber Glass
• Clear (Flint) Glass

Packaging Formats Covered:

• Primary Packaging
• Secondary Packaging

Drug Types Covered:

• Injectable Drugs
• Vaccines
• Biologics & Biosimilars
• Small Molecule Drugs
• Oral Liquid Medicines
• Ophthalmic Drugs

Capacities Covered:

• Less than 10 mL
• 10-50 mL
• 51-100 mL
• Above 100 mL

End Users Covered:

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Contract Packaging Organizations (CPOs)
• Research & Academic Institutes

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Pharmaceutical Glass Packaging Market, By Product Type

• 5.1 Vials
• 5.2 Ampoules
• 5.3 Cartridges
• 5.4 Syringes
• 5.5 Bottles
• 5.6 Tubular Glass Containers
• 5.7 Other Glass Containers

6 Global Pharmaceutical Glass Packaging Market, By Glass Type

• 6.1 Type I (Borosilicate Glass)
• 6.2 Type II (Treated Soda-Lime Glass)
• 6.3 Type III (Soda-Lime Glass)
• 6.4 Amber Glass
• 6.5 Clear (Flint) Glass

7 Global Pharmaceutical Glass Packaging Market, By Packaging Format

• 7.1 Primary Packaging
• 7.2 Secondary Packaging

8 Global Pharmaceutical Glass Packaging Market, By Drug Type

• 8.1 Injectable Drugs
• 8.2 Vaccines
• 8.3 Biologics & Biosimilars
• 8.4 Small Molecule Drugs
• 8.5 Oral Liquid Medicines
• 8.6 Ophthalmic Drugs

9 Global Pharmaceutical Glass Packaging Market, By Capacity

• 9.1 Less than 10 mL
• 9.2 10-50 mL
• 9.3 51-100 mL
• 9.4 Above 100 mL

10 Global Pharmaceutical Glass Packaging Market, By End User

• 10.1 Pharmaceutical Companies
• 10.2 Biotechnology Companies
• 10.3 Contract Development & Manufacturing Organizations (CDMOs)
• 10.4 Contract Packaging Organizations (CPOs)
• 10.5 Research & Academic Institutes

11 Global Pharmaceutical Glass Packaging Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 SCHOTT Pharma AG & Co. KGaA
• 14.2 Gerresheimer AG
• 14.3 Stevanato Group S.p.A.
• 14.4 SGD Pharma
• 14.5 Corning Incorporated
• 14.6 Nipro Corporation
• 14.7 Bormioli Pharma S.p.A.
• 14.8 Shandong Pharmaceutical Glass Co., Ltd.
• 14.9 Stolzle Glass Group
• 14.10 West Pharmaceutical Services, Inc.
• 14.11 Ardagh Group S.A.
• 14.12 DWK Life Sciences GmbH
• 14.13 Beatson Clark Ltd.
• 14.14 Sisecam Group
• 14.15 Owens-Illinois, Inc.